R. Ebert

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

Michael A. Nauck, Markus M. Heimesaat, Jens J. Holst et al. · Journal of Clinical Investigation · 1993 · 1.6K citations · Full text

Medicine, Endocrinology, Pharmacology +15

Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes

Michael A. Nauck, F. Stöckmann, R. Ebert et al. · Diabetologia · 1986 · 1.3K citations · Full text

Medicine, Endocrinology, Pharmacology +13

Incretin Effects of Increasing Glucose Loads in Man Calculated from Venous Insulin and C-Peptide Responses*

Michael A. Nauck, ERWIN HOMBERGER, E. G. Siegel et al. · The Journal of Clinical Endocrinology & Metabolism · 1986 · 875 citations

Medicine, Biochemistry, Endocrinology +17

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.

Michael A. Nauck, Eckart Bartels, R. Ebert et al. · The Journal of Clinical Endocrinology & Metabolism · 1993 · 476 citations

Medicine, Endocrinology, Biochemical Pharmacology +15

Gastric inhibitory polypeptide (GIP) and insulin in obesity: Increased response to stimulation and defective feedback control of serum levels

W. Creutzfeldt, R. Ebert, B. Willms et al. · Diabetologia · 1978 · 211 citations · Full text

Life Sciences, Biochemistry, Endocrinology +14